Valneva reports full year 2023 revenue and cash, provides first 2024 guidance

Valneva reports full year 2023 revenue and cash, provides first 2024 guidance total revenues of €153.7 million, including product sales of €144.6 million product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% excluding covid-19 vaccine sales, product sales grew by 63% compared to 2022 cash position of €126.1 million at december 31, 2023 excludes recent sale of the priority review voucher (prv) for $103 million (€95 million)1                                                                                                                                                                                                                                                                                                                                           reflects significant payments related to the phase 3 lyme disease study, for which valneva's cost contributions are expected to be completed in the first half 20242 first full year 2024 guidance product sales expected between €150 million and €180 million, reflecting continued revenue growth for proprietary products and ixchiq®'s launch-year sales, despite anticipated supply constraints for third-party products and ixiaro® other income anticipated between €95 million and €105 million, including the prv sold in early 2024 for €95 million expected r&d expenses between €65 million and €90 million saint-herblain (france), february 15, 2024 – valneva se (nasdaq: valn; euronext paris: vla) a specialty vaccine company, today reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and r&d expense guidance. the company will publish its 2023 audited consolidated financial statements on march 20, 2024.
VALN Ratings Summary
VALN Quant Ranking